Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.8887
-0.0294 (-3.20%)
At close: Jan 22, 2026, 4:00 PM EST
0.8890
+0.0003 (0.03%)
Pre-market: Jan 23, 2026, 4:05 AM EST
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $493.10K in the quarter ending September 30, 2025, a decrease of -85.58%. This brings the company's revenue in the last twelve months to $4.49M, up 1.51% year-over-year. In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth.
Revenue (ttm)
$4.49M
Revenue Growth
+1.51%
P/S Ratio
0.38
Revenue / Employee
$560,997
Employees
8
Market Cap
3.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | 2.17M | 122.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SciSparc | 1.31M |
| Onconetix | 1.22M |
| Scinai Immunotherapeutics | 1.15M |
| Cardio Diagnostics Holdings | 15.78K |
| Azitra | 7.50K |
ENSC News
- 1 day ago - Ensysce Biosciences Expands Global Opioid Patent Portfolio - Accesswire
- 14 days ago - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Accesswire
- 15 days ago - Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 17 days ago - Ensysce Biosciences Issues Annual Shareholder Letter - Accesswire
- 5 weeks ago - Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - GlobeNewsWire
- 6 weeks ago - Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Accesswire
- 7 weeks ago - Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Accesswire
- 2 months ago - Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - Accesswire